Deferred Tax Assets, Valuation Allowance of Enlivex Therapeutics Ltd. from 31 Dec 2013 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Enlivex Therapeutics Ltd. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2024.
Enlivex Therapeutics Ltd. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $37,294,000, a 11% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Enlivex Therapeutics Ltd. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$37,294,000	+$3,560,000	+11%	31 Dec 2024	20-F	30 Apr 2025	2024	FY
Q4 2023	$33,734,000	+$4,792,000	+17%	31 Dec 2023	20-F	30 Apr 2025	2024	FY
Q4 2022	$28,942,000	+$2,917,000	+11%	31 Dec 2022	20-F	30 Apr 2024	2023	FY
Q4 2021	$26,025,000	+$5,929,000	+30%	31 Dec 2021	20-F	10 Apr 2023	2022	FY
Q4 2020	$20,096,000	+$14,478,000	+258%	31 Dec 2020	20-F	29 Apr 2022	2021	FY
Q4 2019	$5,618,000	+$2,235,000	+66%	31 Dec 2019	20-F	30 Apr 2021	2020	FY
Q4 2018	$3,383,000	+$744,000	+28%	31 Dec 2018	20-F	30 Apr 2021	2020	FY
Q4 2017	$2,639,000	+$501,000	+23%	31 Dec 2017	20-F	30 Apr 2020	2019	FY
Q4 2016	$2,138,000	-$3,627,000	-63%	31 Dec 2016	20-F	30 Apr 2019	2018	FY
Q4 2015	$5,765,000	+$3,974,000	+222%	31 Dec 2015	20-F	24 Feb 2017	2016	FY
Q4 2014	$1,791,000	+$1,479,000	+474%	31 Dec 2014	20-F	29 Mar 2016	2015	FY
Q4 2013	$312,000			31 Dec 2013	20-F	31 Mar 2015	2014	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.